ABP 102 - Abpro Therapeutics/Celltrion
Alternative Names: ABP-102 - Abpro Therapeutics; ABP-102 - Abpro Therapeutics/CelltrionLatest Information Update: 16 Dec 2024
Price :
$50 *
At a glance
- Originator Abpro Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Gastric cancer; Pancreatic cancer